Pluristem Therapeutics, Inc. (PSTI) Receives Consensus Recommendation of “Buy” from Analysts

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has earned an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $3.83.

PSTI has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $3.50 target price on shares of Pluristem Therapeutics in a report on Wednesday, September 6th. Maxim Group set a $3.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 1st. ValuEngine cut shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Seaport Global Securities reissued a “buy” rating and set a $5.00 target price on shares of Pluristem Therapeutics in a report on Friday, October 6th. Finally, Zacks Investment Research cut shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSTI. Renaissance Technologies LLC increased its holdings in Pluristem Therapeutics by 9.1% in the first quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock valued at $1,911,000 after buying an additional 129,000 shares in the last quarter. Psagot Investment House Ltd. increased its holdings in Pluristem Therapeutics by 1,705.2% in the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 122,347 shares in the last quarter. Heritage Investors Management Corp purchased a new position in Pluristem Therapeutics in the third quarter valued at $113,000. Finally, Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 15.0% in the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 34,742 shares in the last quarter. 4.23% of the stock is owned by institutional investors.

Pluristem Therapeutics (NASDAQ PSTI) opened at $1.55 on Friday. Pluristem Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $2.12.

Pluristem Therapeutics (NASDAQ:PSTI) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). research analysts anticipate that Pluristem Therapeutics will post -0.34 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/11/25/pluristem-therapeutics-inc-psti-receives-consensus-recommendation-of-buy-from-analysts.html.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply